Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35081255

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Jun 9
First author
Perl AE

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Perl AE
      type
      Author
    2. name
      Larson RA
      type
      Author
    3. name
      Podoltsev NA
      type
      Author
    4. name
      Strickland S
      type
      Author
    5. name
      Wang ES
      type
      Author
    6. name
      Atallah E
      type
      Author
    7. name
      Schiller GJ
      type
      Author
    8. name
      Martinelli G
      type
      Author
    9. name
      Neubauer A
      type
      Author
    10. name
      Sierra J
      type
      Author
    11. name
      Montesinos P
      type
      Author
    12. name
      Récher C
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Perl AE
      type
      Author
    2. name
      Larson RA
      type
      Author
    3. name
      Podoltsev NA
      type
      Author
    4. name
      Strickland S
      type
      Author
    5. name
      Wang ES
      type
      Author
    6. name
      Atallah E
      type
      Author
    7. name
      Schiller GJ
      type
      Author
    8. name
      Martinelli G
      type
      Author
    9. name
      Neubauer A
      type
      Author
    10. name
      Sierra J
      type
      Author
    11. name
      Montesinos P
      type
      Author
    12. name
      Récher C
      type
      Author
    bibliography ids
    1. nci-bib-ff4ddef5efc417af2b34338a
    book metadata
    content sha256
    acba4850345e4ddeba3142862357e79639445ff4ce501f6c58cea62d22c2fefc
    document type
    citation
    dois
    1. 10.1182/blood.2021011583
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35081255
    immutable id
    pubmed:35081255@acba4850345e4ddeba3142862357e79639445ff4ce501f6c58cea62d22c2fefc
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    23
    name
    Blood
    nlm unique id
    7603509
    pages
    3366-3375
    volume
    139
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35081255
      provenance
      batch id
      3f4d1914d2afe41e9e70
      provider
      NCBI PubMed ESummary
      record sha256
      d631e8d1e3aa7a997044a908a25383b20d0ea820a60f85fba6f8eb47daf32f2c
      response sha256
      0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
      retrieved at
      2026-09-09T23:48:06.522634+00:00
      publication date
      display
      2022 Jun 9
      precision
      day
      year
      2022
      publication types
      1. Journal Article
      2. Randomized Controlled Trial
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35081255/
      title
      Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

      Preserved source evidence · Not medical advice